KPC胰腺癌小鼠模型(P53/TP53杂合子)

键词:胰腺癌,胰腺癌转基因小鼠,KPC,KrasG12D, P53/TP53, Pdx1-Cre

名称:杂合子KPC-胰腺癌小鼠(p53+/-)

是否基因修饰:是,KrasG12D,P53(TP53),Pdx1-Cre

货号:KJ0019

来源:C57BL/6j转基因小鼠

相关基因:特异性相对较强,在小鼠胰腺中,Pdx1-Cre(负责Cre酶特异性表达)开始表达, 使得P53-/-(TP53)(导管细胞基因组中,P53在基因组中部分不完全删除),KrasG12D(K-ras基因常见突变,氨基酸序列中第12位甘氨酸突变为天冬氨酸,Kras蛋白过表达)

成瘤情况介绍:是,成功率接近100%,小鼠12周开始发病,16周左右腹部开始隆起,部分小鼠伴有腹水,腹血。小鼠生存周期可以长达20周。

Keywords: Pancreatic cancer, Pancreatic cancer transgenic mouse, KPC, KrasG12D, P53/TP53, Pdx1-Cre

Name: Heterozygous-KPC-Pancreatic Cancer Mouse (p53+/-)

Genetically Modified: Yes, KrasG12D, P53 (TP53), Pdx1-Cre

Catalog Number: KJ0019

Origin: C57BL/6J transgenic mouse

Related Genes: High specificity; in the mouse pancreas, Pdx1-Cre (responsible for specific Cre recombinase expression) is activated, resulting in P53-/- (TP53) (incomplete knockout of P53 in the ductal cell genome, no functional protein expression), and KrasG12D (a common K-ras mutation where glycine at position 12 is substituted with aspartic acid, leading to Kras protein overexpression).

Tumorigenesis Overview: Yes, with a near 100% success rate. Tumor onset occurs around 12 weeks of age, with abdominal distension observed by 16 weeks, accompanied by ascites and abdominal hemorrhage in some mice. Maximum survival period is 20 weeks.